KR20090099974A - Composition comprising an extract of folium mori for preventing and treating hyperlipidemia or obesity - Google Patents
Composition comprising an extract of folium mori for preventing and treating hyperlipidemia or obesity Download PDFInfo
- Publication number
- KR20090099974A KR20090099974A KR1020080025297A KR20080025297A KR20090099974A KR 20090099974 A KR20090099974 A KR 20090099974A KR 1020080025297 A KR1020080025297 A KR 1020080025297A KR 20080025297 A KR20080025297 A KR 20080025297A KR 20090099974 A KR20090099974 A KR 20090099974A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- obesity
- weight
- fat
- leaf extract
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 68
- 208000008589 Obesity Diseases 0.000 title claims abstract description 23
- 235000020824 obesity Nutrition 0.000 title claims abstract description 23
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 240000000249 Morus alba Species 0.000 claims abstract description 5
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 3
- 239000008213 purified water Substances 0.000 claims abstract description 3
- 239000002904 solvent Substances 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 235000021028 berry Nutrition 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 22
- 239000008280 blood Substances 0.000 abstract description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 20
- 102000016267 Leptin Human genes 0.000 abstract description 8
- 108010092277 Leptin Proteins 0.000 abstract description 8
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract description 8
- 229940039781 leptin Drugs 0.000 abstract description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 4
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 3
- 238000008214 LDL Cholesterol Methods 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 43
- 238000010171 animal model Methods 0.000 description 29
- 239000003814 drug Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 229940079593 drug Drugs 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 238000010586 diagram Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 210000001789 adipocyte Anatomy 0.000 description 10
- 210000003815 abdominal wall Anatomy 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 7
- 230000002611 ovarian Effects 0.000 description 7
- 102000011690 Adiponectin Human genes 0.000 description 6
- 108010076365 Adiponectin Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 235000009200 high fat diet Nutrition 0.000 description 5
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 5
- 229960003105 metformin Drugs 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 240000008415 Lactuca sativa Species 0.000 description 3
- 235000003228 Lactuca sativa Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000004264 Osteopontin Human genes 0.000 description 3
- 108010081689 Osteopontin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 102000005861 leptin receptors Human genes 0.000 description 3
- 108010019813 leptin receptors Proteins 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 2
- 102000014777 Adipokines Human genes 0.000 description 2
- 108010078606 Adipokines Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000000478 adipokine Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- -1 glucose and fructose Chemical class 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000003752 saphenous vein Anatomy 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000239183 Filaria Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000012285 hip pain Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Abstract
Description
본 발명은 상엽 추출물을 유효성분으로 함유하는 고지혈증 또는 비만의 예방 및 치료용 조성물에 관한 것이다.The present invention relates to a composition for the prevention and treatment of hyperlipidemia or obesity containing the extract of the upper leaf as an active ingredient.
[문헌 1] Kurt J. Isselbacher. Harrison's Principles of internal medicine. 13th ed. New York:McGraw-Hill. 1994:446-452
[문헌 2] 국승래, 박영수, 고완규, 김상만, 이득주, 강희철 et. al., 정상군과 비만군에서 허리-둔부 둘레비에 따른 체지방, 고지혈증, 혈압, 혈당과의 관계, 가정의학회지, 18(3), p.317-327, 1997[Ref. 2] Kook Seung-rae, Park Young-soo, Go Wan-kyu, Kim Sang-man, Lee Juk-joo, Kang Hee-chul et. al., The relationship between body fat, hyperlipidemia, blood pressure and blood glucose according to waist-buttock ratio in normal and obese groups, Journal of Family Medicine, 18 (3), p.317-327, 1997
[문헌 3] Kunitomi M, Wada J, Takahashi K, Tsuchiyama Y, Mimura Y, Hida K, Miyatake N, Fujii M, Kira S, Shikata K, Maknio H. Relationship between reduced serum IGF-I levels and accumulation of visceral fat in Japanese men. Int J Obes Relat Metab Disord. 2002;26:361-9.Kunitomi M, Wada J, Takahashi K, Tsuchiyama Y, Mimura Y, Hida K, Miyatake N, Fujii M, Kira S, Shikata K, Maknio H. Relationship between reduced serum IGF-I levels and accumulation of visceral fat in Japanese men. Int J Obes Relat Metab Disord. 2002; 26: 361-9.
[문헌 4] Mitchell M, Armstrong DT, Robker RL, Norman RJ. Adipokines: implications for female fertility and obesity. Reproduction. 2005;130:583-97[4] Mitchell M, Armstrong DT, Robker RL, Norman RJ. Adipokines: implications for female fertility and obesity. Reproduction. 2005; 130: 583-97
[문헌 5] 중약대사전, 김창민 외, 1997, pp2175-2176[Reference 5] Chinese Medicine Dictionary, Changmin Kim et al., 1997, pp2175-2176
[문헌 6] Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol. 2004;287:G1035-43Document 6 Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF. Obese and diabetic db / db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol. 2004; 287: G1035-43
고지혈증은 혈중 콜레스테롤이나 중성지방이 높은 상태로 손등에 노란색 결절이 생기고 발목과 손목 주위에 결절이 발생한다. 그리고 눈꺼풀에 결절이 발생하며 홍채 주위에 하얀 고리가 생기는 증상이 나타난다. 80년대 이후 과식과 동물성 지방의 섭취, 운동부족, 흡연과 과음, 스트레스 등으로 인해 고지혈증 환자가 늘고 있다. 더욱이 육류와 패스트푸드를 좋아하는 젊은이들 가운데 심장병, 뇌졸중에 걸리는 사람이 속출하고 있다. 1차적으로 기름진 음식의 섭취와 운동부족을 꼽을 수 있다. 드물긴 하지만 유전적인 원인에 의해 발병하기도 하고 흡연과 음주, 갱년기이후 성 호르몬의 감소, 그리고 성호르몬, 스테로이드제제, 베타교감신경차단 고혈압약, 이뇨제 등 특정 약물의 장기복용으로 인해 고지혈증이 유발 또는 악화될 수 있다. 이밖에 갑상선기능저하증, 당뇨병, 신장증후군, 간장질환 등이 고지혈증을 일으킬 수도 있다(Kurt J. Isselbacher. Harrison's Principles of internal medicine. 13th ed. New York:McGraw-Hill. 1994:446-452).Hyperlipidemia is a condition that is high in blood cholesterol or triglycerides with yellow nodules on the back of the hand and nodules around the ankles and wrists. Nodules develop on the eyelids and white rings appear around the iris. Since the 1980s, hyperlipidemia has increased due to overeating, animal fat intake, lack of exercise, smoking, heavy drinking and stress. Moreover, young people who like meat and fast food are suffering from heart disease and stroke. Primary consumption is fatty foods and lack of exercise. Rarely, it is caused by genetic causes and causes or worsens hyperlipidemia due to smoking and drinking, decreased post-menopausal sex hormones, and long-term use of certain drugs, such as sex hormones, steroids, beta-sympathetic blockers, and diuretics. Can be. Hypothyroidism, diabetes, kidney syndrome, and liver disease may also cause hyperlipidemia (Kurt J. Isselbacher. Harrison's Principles of internal medicine.13th ed. New York: McGraw-Hill. 1994: 446-452).
고지혈증 치료제는 지나친 혈중 지방, 특히 콜레스테롤과 중성지방의 수치를 낮추기 위해 사용된다. 지질 대사에 사용되는 주요 약들은 스타틴, 담즙산 차단제, 피브르산 유도체 등이 있다. 이 약들은 각각 다른 기전으로 작용한다. 이 밖에도 생선기름과 같은 천연 식이식품이 사용되기도 한다. 고지혈증 치료제의 선택은 증가된 지단백의 종류에 따라서 이들 약제를 복합적으로 사용하기도 한다. 이 약들은 매일 경구로 장기간 복용이 필요하다.Hyperlipidemia drugs are used to lower levels of excess blood fat, especially cholesterol and triglycerides. Major drugs used for lipid metabolism include statins, bile acid blockers and fibric acid derivatives. Each of these drugs acts in a different mechanism. In addition, natural dietary foods such as fish oil may be used. The choice of therapeutic agents for hyperlipidemia may be a combination of these drugs, depending on the type of lipoprotein that is increased. These drugs require long-term oral daily use.
하지만 이러한 약들은 콜레스테롤과 혈중농도를 효과적으로 떨어뜨리는 만큼 부작용을 가지고 있다. 스타틴의 경우 구역, 두통, 복통과 설사나 변비가 나타날 수 있어 근육에 염증을 유발할 수 있고 담즙산 차단제는 비타민 A, D, K의 장 흡수가 떨어질 수 있으므로, 이들 비타민 보충이 필요하다. 그리고 피브리산 유도체는 신장 질환, 간질환 또는 담낭 질환에는 부적합한 약이다. 따라서 이들 제제를 대신할 의약품 및 천연물이 함유된 기능성 식품 등의 개발에 대한 요구가 커지고 있다(국승래, 박영수, 고완규, 김상만, 이득주, 강희철 등, 정상군과 비만군에서 허리-둔부 둘레비에 따른 체지방, 고지혈증, 혈압, 혈당과의 관계, 가정의학회지, 1997, 18(3), p.317-327).However, these drugs have side effects as much as they effectively lower cholesterol and blood levels. Statins can cause nausea, headache, abdominal pain and diarrhea or constipation, which can cause muscle inflammation, and bile acid blockers can reduce the intestinal absorption of vitamins A, D, and K. And fibric acid derivatives are unsuitable drugs for kidney disease, liver disease or gallbladder disease. Therefore, there is a growing demand for the development of pharmaceuticals and functional foods containing natural products (Kuk Seung-rae, Park Young-soo, Ko Wan-kyu, Kim Sang-man, Lee Juk-joo, Kang Hee-chul, etc.). Relationship between Body Fat, Hyperlipidemia, Blood Pressure, and Blood Sugar, Journal of Family Medicine, 1997, 18 (3), p.317-327).
비만은 체지방이 지나치게 축적되는 상태로 키에 따라 계산되는 건강한 체중의 최대치보다도 적어도 20%이상 체중이 초과하는 경우에 비만으로 여긴다. 비만은 장기와 관절에 압박을 주기 때문에 등의 통증, 엉덩이와 무릎의 통증, 그리고 숨이 가빠지는 것 등 여러 가지 건강문제의 원인이 된다. Obesity is regarded as obesity when the body fat is excessively accumulated and the body weight exceeds at least 20% more than the maximum value of the healthy weight calculated according to the height. Obesity puts pressure on your organs and joints, causing a variety of health problems, including back pain, hip and knee pain, and shortness of breath.
비만은 관상동맥 질환, 뇌졸중, 고혈압과 같은 잠재적으로 치명적일 수 있는 질환들의 위험을 증가시키고 우울증과 같은 심리적인 문제도 불러온다. 비만은 다양한 만성질환의 위험을 증가시킨다. 비만한 사람들은 혈중 콜레스테롤 수치가 높으며 이로 인해 동맥의 내벽에 지방이 축적되는 동맥경화증의 위험을 증가시키며, 동맥경화는 고혈압과 관상동맥 질환의 원인이 된다. 동맥 혈전증과 혈전에 의해 혈관이 막히는 색전증도 자주 나타나며, 담석증의 위험도 더 크고, 당뇨병에도 더 잘 걸리는 경향이 있다. 유방암과 자궁암 같은 여러 암 역시 비만한 사람에게 더 흔하 다. 과중한 몸무게는 관절들을 압박하는데, 특히 엉덩이와 무릎의 골관절염은 비만한 사람들에게 흔하다. 호흡성 질환으로 수면 무호흡 역시 비만한 사람들과 관련이 있다. 현재 비만을 판단하는 가장 일반적인 기준은 복부 지방의 양 및 분포로 알려져 있다. (Kunitomi M, Wada J, Takahashi K, Tsuchiyama Y, Mimura Y, Hida K, Miyatake N, Fujii M, Kira S, Shikata K, Maknio H. Relationship between reduced serum IGF-I levels and accumulation of visceral fat in Japanese men. Int J Obes Relat Metab Disord. 2002;26:361-9.)Obesity increases the risk of potentially fatal diseases such as coronary artery disease, stroke, and high blood pressure and also raises psychological problems such as depression. Obesity increases the risk of various chronic diseases. Obese people have high blood cholesterol levels, which increases the risk of atherosclerosis, which accumulates fat in the lining of the arteries, which causes high blood pressure and coronary artery disease. Arterial thrombosis and embolism in which blood vessels are clogged by blood clots often appear, and the risk of cholelithiasis is greater, and diabetes tends to be more likely. Several cancers, such as breast and uterine cancers, are also more common in obese people. Excessive weight compresses joints, especially osteoarthritis of the hips and knees is common in obese people. Sleep apnea as a respiratory disease is also associated with obese people. The most common criterion for determining obesity at present is the amount and distribution of abdominal fat. (Kunitomi M, Wada J, Takahashi K, Tsuchiyama Y, Mimura Y, Hida K, Miyatake N, Fujii M, Kira S, Shikata K, Maknio H. Relationship between reduced serum IGF-I levels and accumulation of visceral fat in Japanese men Int J Obes Relat Metab Disord. 2002; 26: 361-9.)
전 세계적으로 비만 환자는 계속해서 증가하고 있으며, 비만의 원인 규명을 위한 노력이 경주되고 있으며, 이러한 노력의 결과 운동 등의 감소에 따른 에너지 항상성의 이상에 의해 초래되는 것으로 알려져 있다. 치료방법으로는 식단조절과 운동이 필수적이며 식욕 억제 약물을 사용해 볼 수 있으나 부작용 때문에 거의 추천되지 않는다. 그러므로 예로부터 사용되어 인체에 무해함이 입증되어 온 천연물 추출물을 이용한 치료제의 경우, 기존 치료제에 의한 내성이나 안전성 문제를 극복할 수 있다. (Mitchell M, Armstrong DT, Robker RL, Norman RJ. Adipokines: implications for female fertility and obesity. Reproduction. 2005;130:583-97)Obesity patients are increasing all over the world, and efforts are being made to determine the cause of obesity. As a result of these efforts, it is known that the cause of obesity is caused by abnormality of energy homeostasis due to the reduction of exercise. As a treatment, diet and exercise are essential, and appetite suppressants can be used, but they are rarely recommended due to side effects. Therefore, in the case of a therapeutic using a natural product extract that has been used since ancient times and has been proved to be harmless to the human body, it is possible to overcome resistance or safety problems caused by existing therapeutics. (Mitchell M, Armstrong DT, Robker RL, Norman RJ. Adipokines: implications for female fertility and obesity.Reproduction. 2005; 130: 583-97)
한방에서 약재로 사용되어 온 천연물을 이용한 한방 기능성 품목들이 인기가 높다. 항고지혈증 및 항비만 효과를 지닌 천연물 성분을 개발한다면 큰 수익을 창출할 수 있을 것이다. Herbal functional items using natural products that have been used as herbal medicine are popular. Developing natural ingredients with anti-hyperlipidemic and anti-obesity effects could generate big profits.
상엽은 뽕나무과 식물 상백나무 (Morus alba L.)의 건조된 잎이다. 대부분의 말린 잎몸은 쪼그라들어 둥글고 부서져 있다. 형태가 완전한 것은 달걀 모양 또는 넓은 달걀 모양이며 길이는 8~13 cm, 너비는 7~11 cm이다. 끝은 뾰족하고 가장자리는 톱니 모양이거나 때로는 불규칙하게 갈라지며 기부는 절단형이거나 원형 또는 심장형이다. 윗면은 황록색이고 조금 광택이 있으며 잎맥을 따라 가늘고 작은 부드러운 털이 있다. 아랫면은 색이 약간 엷고 잎맥이 돌출되어 있으며 작은 잎맥은 망상으로 교차되고 가는 털이 밀생한다. 질은 취약하고 부서지기 쉽다. 냄새가 조금 있으며 맛은 싱겁고 조금 쓰고 떫다. 잎몸이 완전하고 크고 두껍고 황록색이며 질이 취약하며 불순물이 없는 것을 양품으로 한다. 일반적으로 10~11월에 서리가 내린 후에 채집하여 이물질을 제거하고 햇볕에 말린 후 약재로 사용한다(중약대사전, 김창민 외, 1997, pp2175-2176).The upper leaves of the mulberry hawthorn ( Morus It is dried leaf of alba L.). Most dried leaves are crunchy and rounded. The complete form is egg-shaped or broad egg-shaped, 8-13 cm long and 7-11 cm wide. The tip is pointed, the edge is serrated or sometimes irregularly divided and the base is cut or round or heart shaped. The upper side is yellowish green and a little gloss, with thin small soft hairs along the leaf veins. The lower side is slightly light in color and has leaf veins protruding. The small leaf veins intersect with reticular hairs and dense hairs. Quality is vulnerable and brittle It has a little smell and tastes fresh and bitter. Leaf body is full, big, thick, yellowish green, poor quality, free of impurities. Generally, it is collected after frost falls in October ~ November to remove foreign substances, dried in sun and used as medicine (Chinese medicine dictionary, Kim Chang-min et al., 1997, pp2175-2176).
상엽에는 항당뇨병의 작용과 filaria에 의한 림프관염에 긍정적인 치료 효과가 있으며, 하지의 상피종(象皮腫)에 상당한 연화, 부종 제거 작용이 있음이 증명되었다. 그리고 풍을 제거하고 열을 내리며 양혈(血)하고 눈을 밝게 하는 효능이 있다. 풍온발열(風溫發熱), 두통, 목적(目赤), 구갈(口渴), 폐열(肺熱)로 인한 해수(咳嗽), 풍비(졸중풍), 은진(담마진)을 치료한다. (중약대사전, 김창민 외, 1997, pp2176-2177) 지금까지 상엽 추출물 또는 일부 구성성분의 혈압강하, 혈액 유동성 향상, 중금속 흡착과 해독효과 등의 여러 가지 효능이 밝혀지고 있으나, 항고지혈증 및 항비만 효과에 대한 연구는 수행되지 않았다. 이에 본 발명자들은 상엽추출물을 유효성분으로 함유하는 조성물이 고지방사료를 투여한 실험동물에서의 혈중 총 콜레스테롤, 트리글리세라이드, LDL, 체중, 복부 및 난소 주위 지방 중량, 혈중 렙틴 및 아디포넥틴 함량들의 감소 및 HDL 함량의 증가를 확인함으로써, 본 발명을 완성하였다.The upper lobe has a positive therapeutic effect on antidiabetic and filaria-induced lymphadenitis, and it has been demonstrated that there is a significant softening and edema removal effect on the epithelium of the lower extremities. It also has the effect of removing wind, lowering heat, bleeding and brightening eyes. Wind-temperature fever, headache, purpose (目赤), gugal (口渴), waste heat (咳嗽) due to sea water (咳嗽), wind rain (stroke wind), Eunjin (damagejin) is treated. (Chinese medicinal metabolism, Kim Chang-min et al., 1997, pp2176-2177) Until now, various effects such as lowering blood pressure, improving blood flow, heavy metal adsorption and detoxification effects of upper leaf extracts or some constituents have been found. No study was conducted. Therefore, the present inventors found that the composition containing the leaf extract as an active ingredient reduced total blood cholesterol, triglycerides, LDL, body weight, abdominal and ovarian fat weight, blood leptin and adiponectin contents, and HDL in experimental animals administered high fat diet. By confirming the increase in content, the present invention was completed.
상기 목적을 달성하기 위하여, 본 발명은 상엽 추출물을 유효성분으로 함유하는 고지혈증 또는 비만의 예방 및 치료용 약학조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention and treatment of hyperlipidemia or obesity containing the extract as an active ingredient.
또한 본 발명은 상엽 추출물을 유효성분으로 함유하는 고지혈증 또는 비만의 예방 및 개선용 건강기능식품을 제공한다.In another aspect, the present invention provides a dietary supplement for the prevention and improvement of hyperlipidemia or obesity containing the extract as an active ingredient.
본원에서 정의되는 추출물은 정제수를 포함한 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매 바람직하게는 물에 가용한 추출물을 포함한다.Extracts as defined herein include water, including purified water, lower alcohols having 1 to 4 carbon atoms or mixed solvents thereof, preferably extracts soluble in water.
상기 상엽 추출물은 뽕나무의 잎, 열매, 뿌리 또는 가지, 바람직하게는, 잎으로부터 추출된 추출물을 포함한다. The leaf extract may include an extract extracted from the leaves, berries, roots or branches of the mulberry, preferably, the leaves.
상기 상엽 추출물의 약학조성물은 총 중량에 대하여 0.1 내지 50 중량%로 사용이 가능하다. The pharmaceutical composition of the upper leaf extract can be used in 0.1 to 50% by weight based on the total weight.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 상엽 추출물은 하기와 같이 수득될 수 있다. The leaf extract of the present invention can be obtained as follows.
본 발명의 상엽을 구입하여 세척 후, 음건하여 상엽 시료 중량의 약 1 내지 40배, 바람직하게는 약 1 내지 30배에 달하는 부피의 물, 에탄올 및 메탄올 등과 같은 C1 내지 C4의 저급알콜의 극성 용매 또는 이들의 약 1: 0.1 내지 1: 10의 혼합비를 갖는 혼합용매로, 바람직하게는 물로, 약 0℃ 내지 200 ℃, 바람직하게는 약 50℃ 내지 150℃에서 약 1시간 내지 1일 동안 냉침 추출법, 열수추출, 환류 순환 추출 또는 압력추출 등의 추출방법을 사용하여, 바람직하게는 열수 추출법을 수행하여 감압여과, 농축 및 동결 건조하여 상엽추출물을 수득할 수 있다. After purchasing and washing the upper leaf of the present invention, it is dried and dried to lower the alcohol content of C 1 to C 4 such as water, ethanol and methanol in volumes of about 1 to 40 times the weight of the upper leaf sample, preferably about 1 to 30 times. Polar solvent or a mixed solvent having a mixing ratio of about 1: 0.1 to 1:10, preferably with water, at about 0 ° C to 200 ° C, preferably at about 50 ° C to 150 ° C for about 1 hour to 1 day Using extraction methods such as cold needle extraction, hot water extraction, reflux circulation extraction or pressure extraction, preferably hot water extraction may be carried out under reduced pressure filtration, concentration and freeze-drying to obtain the leaf extract.
본 발명은 상기의 제조공정으로 얻어진 상엽 추출물을 유효성분으로 함유하는 고지혈증 및 비만의 예방 및 치료용 약학조성물을 제공한다.The present invention provides a pharmaceutical composition for the prevention and treatment of hyperlipidemia and obesity containing the upper leaf extract obtained by the above manufacturing process as an active ingredient.
본 발명에 따른 상엽추출물을 포함하는 약학조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. Pharmaceutical compositions comprising the extract of the lobe according to the present invention, powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, external preparations, suppositories and sterile injectable solutions, respectively, according to a conventional method. Can be formulated and used.
상엽추출물을 포함하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨,말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화 할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. Carriers, excipients, and diluents that may be included in the composition comprising the leaf extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants are usually used.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 상엽추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로스(sucrose) 또는 락토오스 (lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose ( It is prepared by mixing sucrose or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름,에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used.
좌제의 기제로는 위텝솔 (witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 상엽추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. The preferred dosage of the lobe extract of the present invention depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.
그러나 바람직한 효과를 위해서, 본 발명의 상엽추출물은 1일 0.0001 내지 100 mg/kg으로, 바람직하게는 0.001 내지 10 mg/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. However, for the preferred effect, the leaf extract of the present invention is preferably administered in 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
본 발명의 상엽추출물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 (intracerebroventricular) 주사에 의해 투여될 수 있다. The leaf extract of the present invention can be administered to various mammals such as mice, mice, livestock, humans. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
본 발명은 상엽추출물을 함유하는 고지혈증 및 비만의 예방 및 개선용 건강기능식품을 제공한다. The present invention provides a dietary supplement for the prevention and improvement of hyperlipidemia and obesity containing the leaf extract.
본 발명의 상엽추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다. Examples of the food to which the leaf extract of the present invention can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.
또한, 고지혈증 또는 비만의 예방 효과를 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 상엽추출물의 양은 일반적으로 본 발명의 건강 기능 식품 조성물은 전체 식품 중량의 0.01 내지 50 중량%, 바람직하게는 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다.It may also be added to foods or beverages for the purpose of preventing hyperlipidemia or obesity. At this time, the amount of the lettuce extract in the food or beverage is generally added to the dietary supplement composition of the present invention 0.01 to 50% by weight, preferably 0.01 to 15% by weight of the total food weight, the health beverage composition is 100 It can be added at a ratio of 0.02 to 5 g, preferably 0.3 to 1 g, based on ml.
본 발명의 건강기능식품은 정제, 캡슐제, 환제, 액제 등의 형태를 포함한다. Health functional food of the present invention includes the form of tablets, capsules, pills, liquids and the like.
본 발명의 건강 음료 조성물은 지시된 비율로 필수 성분으로서 상기 상엽추출물을 함유하는 외에는 다른 성분에는 특별한 제한점이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등의 디사카라이드, 예를 들어 말토스, 슈크로스 등의 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. The health beverage composition of the present invention is not particularly limited in the other components except the above-mentioned leaf extract as an essential component in the indicated ratio, and may contain various flavors or natural carbohydrates, etc. as additional ingredients, as in general beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose, for example polysaccharides such as maltose and sucrose, and conventional sugars such as dextrin and cyclodextrin. And sugar alcohols such as xylitol, sorbitol, and erythritol.
상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있 다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g이다.As flavoring agents other than those mentioned above, natural flavoring agents (tautin, rebaudioside A, glycyrzin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of such natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 상엽추출물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다.In addition to the above, the leaf extract of the present invention is a variety of nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, such as flavoring agents, coloring and neutralizing agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like.
그밖에 본 발명의 상엽추출물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition, the leaf extract of the present invention may contain a fruit flesh for the production of natural fruit juice and fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
본 발명의 상엽 추출물을 고지방사료를 투여한 실험 동물의 혈중 총 콜레스테롤, 트리글리세라이드, LDL-콜레스테롤, 체중, 복부 및 난소주위의 지방 중량, 혈중 렙틴 및 아디포넥틴 함량의 감소 또는 HDL-콜레스테롤 함량의 증가에 대한 효과를 확인함으로써, 고지혈증 또는 비만의 예방 및 치료용 약학조성물 또는 건강기능식품으로 유용하게 이용할 수 있다.The total leaf, cholesterol, triglyceride, LDL-cholesterol, body weight, fat weight around the abdomen and ovary, blood leptin and adiponectin, or HDL-cholesterol content in experimental animals By confirming the effect on, it can be usefully used as a pharmaceutical composition or health functional food for the prevention and treatment of hyperlipidemia or obesity.
이하, 본 발명을 하기 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by the following Examples and Experimental Examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예, 참고예 및 실험예에 의해 한정되는 것은 아니다.However, the following Examples and Experimental Examples are only illustrative of the present invention, the contents of the present invention is not limited by the following Examples, Reference Examples and Experimental Examples.
참고예Reference Example 1. 실험 재료의 준비 1. Preparation of Experimental Materials
1-1. 실험동물모델 선정1-1. Selection of experimental animal model
120 마리의 성숙한 암컷 ICR 마우스를 7일간 실험실 환경에 적응 시킨 후 사용하였으며, 6일간의 40% beef tallow가 함유된 AIN-76A 고지방사료 (Dyets, PA, USA)에 적응성을 나타내는 실험동물을 선정하였다. 실험 전 기간 동안 정상 사료를 공급한 정상대조군, 실험 전 기간 동안 고지방 사료를 공급한 비교대조군(표 1 참조), 고지방사료 공급 1주일 후부터 12주간 1일 1회 농도 250mg/kg 메트포민(metformin)을 경구투여한 대조실험군 및 고지방사료 공급 1주일 후부터 12주간 1일 1회 각각의 농도 125, 250, 500mg/kg 상엽추출물을 경구투여한 실험군으로 총 10마리씩 6군으로 구분하였다(표 2 참조). 120 adult female ICR mice were used after 7 days of acclimatization in the laboratory environment, and experimental animals were selected that were adapted to AIN-76A high fat diet (Dyets, PA, USA) containing 40% beef tallow for 6 days. . The normal control group fed the normal diet for the pre-experimental period, the comparative control group fed the high-fat diet for the pre-experimental period (see Table 1), and the
1-2. 실험시약1-2. Experimental reagent
대조약물인 경구용 혈당강하제 메트포민(metformin)은 Wako Pure chemical (Osaka, Japan)에서 구입하였다. The oral hypoglycemic drug metformin was purchased from Wako Pure Chemical (Osaka, Japan).
실시예 1. 상엽 추출물의 제조Example 1 Preparation of Leaf Extract
상엽은 효성약업사 (대구, 한국)에서 구입하여 물로 세척하여 음건 후 건조중량 200g에 물을 1 : 6.5 (w/v)의 비율로 1.3L를 넣은 후 100℃에서 150분 동안 추출하였다. 추출액을 여과지(Whatman, No.4)로 여과한 후 원심분리기로(Centrifuge SUPRA 22K, Hanil Science Industrial Co., Ltd. Korea) 원심분리하고 동결건조하여 상엽 추출물 40.02 g을 얻어 하기 실험예에 사용하였다. The upper leaves were purchased from Hyosung Pharmaceutical Co., Ltd. (Daegu, Korea), washed with water, and then dried in 200 g of dry weight in a ratio of 1: 6.5 (w / v) at a ratio of 1: 6.5 (w / v) and extracted at 100 ° C. for 150 minutes. The extract was filtered through filter paper (Whatman, No. 4), centrifuged in a centrifuge (Centrifuge SUPRA 22K, Hanil Science Industrial Co., Ltd. Korea), and lyophilized to obtain 40.02 g of upper leaf extract, which was used in the following experimental example. .
실험예 1. 체중감소 측정Experimental Example 1. Measurement of weight loss
상기 참조예 1-1의 실험동물들의 체중을 측정하기 위해서 고지방 사료를 투여한 7일, 21일, 35일, 49일, 63일, 77일, 83일 및 84일째에 각각 측정하였다. 실험결과, 도 1에서 나타내는 바와 같이 농도-의존적으로 체중이 감소하는바, 500mg/kg 및 250 mg/kg 상엽 추출물이 처리된 동물에서는 49일부터 고지방사료만을 공급한 실험동물보다 급격히 체중이 감소되었으며, 125 mg/kg 상엽추출물이 처리된 동물에서는 63일부터 고지방사료만을 공급한 실험동물과 뚜렷한 차이를 보이며 체중이 감소함을 확인하였다(표 3 및 도 1 참조). In order to measure the body weight of the experimental animals of Reference Example 1-1, it was measured on the 7th, 21st, 35th, 49th, 63rd, 77th, 83rd and 84th days of high fat feed administration, respectively. As a result, as shown in Figure 1 weight-dependently decrease in weight, in the animal treated with 500mg / kg and 250 mg / kg upper leaf extract was significantly reduced body weight than the experimental animals fed only high fat feed from
실험예Experimental Example 2. 난소주위 지방 중량 측정 2. Weight measurement around the ovary
상기 참조예 1-1의 실험동물들의 최종 희생일(84일째)에 난소 주위 지방을 분리한 다음 습중량을 측정하였다. 실험결과, 하기 표 4에 나타내는 바와 같이 상엽 추출물이 처리된 실험동물에서는 고지방사료만을 공급한 실험동물들의 지방 중량 보다 급격히 감소되었음을 확인하였다(표 4 참조). On the final sacrifice day (day 84) of the experimental animals of Reference Example 1-1, the periovary fat was separated, and the wet weight was measured. As a result, as shown in Table 4, it was confirmed that the experimental animal treated with the upper leaf extract was rapidly reduced than the fat weight of the experimental animals fed only the high fat feed (see Table 4).
실험예Experimental Example 3. 혈청화학검사 3. Serum Chemistry
상기 참조예 1-1의 실험동물들을 마취 하에서 복대정맥으로부터 약 1 ml의 혈액을 채취하고 3000rpm으로 원심분리하여 혈청을 분리한 후, 혈중 총 콜레스테롤, 트리글리세라이드, LDL 및 HDL의 함량을 혈액자동분석장치(AU400, Olympus, Japan)를 이용하여 각각 측정하였다. About 1 ml of blood was collected from the abdominal vein under anesthesia and the serum was separated by centrifugation at 3000 rpm, and the blood total analysis of total cholesterol, triglyceride, LDL and HDL in blood was performed automatically. Measurement was carried out using an apparatus (AU400, Olympus, Japan).
실험결과, 상엽 추출물을 처리한 동물에서는 혈청 중 총 콜레스테롤 수치, 트리글리세라이드 및 LDL의 수치는 고지방사료를 투여한 실험동물에 비해 뚜렷이 감소하였으며(도 2 내지 도 4 참조), HDL 수치는 지방사료를 투여한 실험동물에 비해 뚜렷이 증가함을 확인하였다(도 5 참조). As a result, the total cholesterol level, triglyceride and LDL levels in serum were significantly decreased in the animals treated with the upper leaf extract (see FIGS. 2 to 4). It was confirmed that the marked increase compared to the experimental animals administered (see Figure 5).
실험예 4. 혈중 렙틴 함량 측정Experimental Example 4. Measurement of Leptin Content in Blood
상엽 추출물의 혈중 렙틴 함량의 감소를 확인하기 위해 기존 문헌에 기재된 방법을 이용하여 하기와 같이 실험하였다(Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am. J. Physiol. Gastrointest. Liver Physiol. 2004;287:G1035-43).In order to confirm the reduction of leptin content in the blood of the upper leaf extract, the following experiment was conducted using the method described in the literature (Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF. Obese and diabetic db / db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin.Am J. Physiol.Gastrointest.Liver Physiol. 2004; 287: G1035-43).
상기 참조예 1-1의 실험동물들을 최종 희생일에 마취 하에서 복대정맥으로부터 혈액을 채취하고 3000rpm으로 원심분리하여 혈청을 분리하였다. 혈중 렙틴 함량은 방사면역측정법 킷트 (radioimmunoassay kit, Linco Research, MO, USA)를 사용하여 측정하였다.The blood of the experimental animals of Reference Example 1-1 was collected from the saphenous vein under anesthesia on the last sacrifice day and centrifuged at 3000 rpm to separate serum. Blood leptin content was measured using a radioimmunoassay kit (Linco Research, MO, USA).
실험결과, 도 6에서 나타내는 바와 같이 상엽 추출물을 처리한 동물에서는 혈중 렙틴 함량의 수치는 고지방사료를 투여한 실험동물에 비해 뚜렷이 감소함을 확인하였다(도 6 참조). As a result, as shown in FIG. 6, the blood leptin content was significantly decreased in the animals treated with the extract of the upper lobe compared to the animals fed the high fat feed (see FIG. 6).
실험예 5. 혈중 아디포넥틴 함량 측정Experimental Example 5. Determination of Adiponectin Content in Blood
상엽 추출물의 혈중 아디포넥틴의 감소효과를 확인하기 위해 기존 문헌에 기재된 방법을 이용하여 하기와 같이 실험하였다 (Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am. J. Physiol. Gastrointest. Liver Physiol. 2004;287:G1035-43).In order to confirm the reduction effect of adiponectin in the blood of the extract of the upper leaf was experimented as follows using the method described in the existing literature (Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF. Obese and diabetic db / db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin.Am J. Physiol.Gastrointest.Liver Physiol. 2004; 287: G1035-43).
상기 참조예 1-1의 실험동물들을 최종 희생일에 마취 하에서 복대정맥으로부터 혈액을 채취하고 3000rpm으로 원심분리하여 혈청을 분리하였다. 혈중 아디포넥틴 함량은 ELISA 킷트 (Otsuka Pharm., Japan)를 사용하여 측정하였다.The blood of the experimental animals of Reference Example 1-1 was collected from the saphenous vein under anesthesia on the last sacrifice day and centrifuged at 3000 rpm to separate serum. Blood adiponectin content was measured using an ELISA kit (Otsuka Pharm., Japan).
실험결과, 도 7에서 나타내는 바와 같이 상엽 추출물을 처리한 동물에서는 아디포넥틴 함량의 수치는 고지방사료를 투여한 실험동물에 비해 뚜렷이 증가함을 확인하였다(도 7 참조).As a result, as shown in FIG. 7, the adiponectin content in the animal treated with the upper leaf extract was significantly increased compared to the experimental animal administered with the high fat feed (see FIG. 7).
실험예 6. 지방의 조직병리학적 변화Experimental Example 6 Histopathological Changes of Fat
난소주위 지방 및 복벽에 부착된 지방 조직을 적출하여, 포매를 실시한 다음 3~4㎛의 절편을 준비하고, Hematoxylin-Eosin 염색 하에서 광학현미경을 이용하여 이상 병변 유무를 관찰하였다. 난소 주위 지방 및 복벽 지방 세포의 평균 직경을 자동영상분석장치 (DMI-300, Daegu, Korea)를 이용하여 산출하였다. Peripheral ovarian fat and adipose tissue attached to the abdominal wall were removed, embedded, and then sections of 3 to 4 μm were prepared. Abnormal lesions were observed using an optical microscope under Hematoxylin-Eosin staining. The mean diameters of the ovarian fat and abdominal wall fat cells were calculated using an automatic image analyzer (DMI-300, Daegu, Korea).
6-1. 난소 주위의 지방세포의 평균직경 측정6-1. Average diameter measurement of fat cells around the ovary
실험결과, 도 8에서 나타내는 바와 같이 상엽 추출물을 처리한 동물에서는 난소주위 지방 세포의 평균 직경 수치는 고지방사료를 투여한 실험동물에 비해 뚜렷이 감소함을 확인하였고(도 8 참조), 또한, 자동영상분석장치로 관찰된 바와 같이 고지방사료 공급 대조군에서는 현저한 지방세포 비대가 관찰되었으나, 500mg/kg 상엽 추출물을 처리한 실험동물에서는 정상대조군(a)과 유의한 지방세포의 양상을 확인하였다(도 9 참조). As a result, as shown in FIG. 8, the average diameter of the ovarian fat cells was significantly decreased in the animals treated with the upper lobe extract as compared to the animals fed the high fat feed (see FIG. 8). As observed by the analytical device, a significant fat cell enlargement was observed in the high fat feed control group, but the normal control group (a) and significant fat cell patterns were observed in the experimental animals treated with 500 mg / kg upper leaf extract (see FIG. 9). ).
6-2. 난소 주위의 복벽 지방의 두께 측정6-2. Measurement of the thickness of the abdominal wall fat around the ovary
실험결과, 도 10 내지 도 11에서 나타내는 바와 같이 상엽 추출물을 처리한 동물에서는 복벽 지방의 두께 및 복벽지방의 평균 직경 수치는 고지방사료를 투여한 실험동물에 비해 뚜렷이 감소함을 확인하였고(도 10 내지 도 11 참조), 또한, 자동영상분석장치로 관찰된 바와 같이 고지방사료 공급 대조군에서는 현저한 지방세포 비대가 관찰되었으나, 상엽추출물을 투여한 실험동물에서 농도의존적으로 억제되는것을 확인하였다(도 12 참조). As a result, as shown in Figures 10 to 11, in the animal treated with the upper leaf extract, the thickness of the abdominal wall fat and the mean diameter value of the abdominal wall fat were confirmed to be markedly reduced compared to the experimental animals to which the high fat feed was administered (FIGS. 10 to 10). In addition, as observed with the automatic image analysis device, a significant fat cell hypertrophy was observed in the high fat feed control group, but it was confirmed that the concentration-dependent inhibition in the experimental animals administered with the lobe extract (see FIG. 12). .
도 1는 상엽추출물의 고지방사료를 투여한 실험동물에 대한 체중 감소 효과를 나타낸 도이며 1 is a diagram showing the weight loss effect on the experimental animals administered high fat feed of the leaf extract
도 2는 상엽추출물의 고지방사료를 투여한 실험동물에 대한 혈청 중 총 콜레스테롤 감소 효과를 나타낸 도이고, Figure 2 is a diagram showing the effect of reducing total cholesterol in serum for the experimental animals administered high fat feed of the leaf extract,
도 3은 상엽추출물의 고지방사료를 투여한 실험동물에 대한 혈청중 트리글리세라이드 감소 효과를 나타낸 도이며,Figure 3 is a diagram showing the effect of reducing triglycerides in serum for the experimental animals administered high fat feed of the leaf extract,
도 4는 상엽추출물의 고지방사료를 투여한 실험동물에 대한 혈청 중 LDL-콜레스테롤 감소 효과를 나타낸 도이고,Figure 4 is a diagram showing the effect of reducing LDL-cholesterol in the serum of the experimental animals administered high-fat feed of the leaf extract,
도 5는 상엽추출물의 고지방사료를 투여한 실험동물에 대한 혈청 중 HDL-콜레스테롤 증가 효과를 나타낸 도이며,Figure 5 is a diagram showing the effect of increasing HDL-cholesterol in the serum for experimental animals administered high fat feed of the leaf extract,
도 6은 상엽추출물의 고지방사료를 투여한 실험동물에 대한 혈청 중 렙틴 함량의 감소 효과를 나타낸 도이고, Figure 6 is a diagram showing the effect of reducing the leptin content in the serum for experimental animals administered high fat feed of the leaf extract,
도 7은 상엽추출물의 고지방사료를 투여한 실험동물에 대한 혈청 중 아디포넥팀 함량의 증가 효과를 나타낸 도이며,Figure 7 is a diagram showing the effect of increasing the content of adiponectim in the serum for experimental animals administered high fat feed of the leaf extract,
도 8은 상엽추출물의 고지방사료를 투여한 실험동물에 대한 난소주위 지방 세포의 평균직경을 나타낸 도이고,Figure 8 is a diagram showing the average diameter of the ovarian fat cells around the experimental animals administered high fat feed of the leaf extract,
도 9는 상엽추출물의 고지방사료를 투여한 실험동물에 대한 난소주위 지방 세포를 영상학적으로 나타낸 도이며,9 is a diagram illustrating the ovarian fat cells around the experimental animals administered with the high fat feed of the leaf extract.
도 10은 상엽추출물의 고지방사료를 투여한 실험동물에 대한 축적된 복벽 지 방의 두께의 감소 효과를 나타낸 도이고,10 is a diagram showing the effect of reducing the thickness of the accumulated abdominal wall fat for experimental animals administered high fat feed of the leaf extract,
도 11은 상엽추출물의 고지방사료를 투여한 실험동물에 대한 복벽 지방 세포의 평균직경을 나타낸 도이며,11 is a view showing the average diameter of the abdominal wall fat cells for the experimental animals administered the high fat feed of the leaf extract,
도 12는 상엽추출물의 고지방사료를 투여한 실험동물에 대한 복벽 지방세포를 영상학적으로 나타낸 도이다. FIG. 12 is a diagram illustrating the abdominal wall fat cells of experimental animals to which the high-fat feed of the lobe extract was imaged.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080025297A KR20090099974A (en) | 2008-03-19 | 2008-03-19 | Composition comprising an extract of folium mori for preventing and treating hyperlipidemia or obesity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080025297A KR20090099974A (en) | 2008-03-19 | 2008-03-19 | Composition comprising an extract of folium mori for preventing and treating hyperlipidemia or obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20090099974A true KR20090099974A (en) | 2009-09-23 |
Family
ID=41358409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020080025297A KR20090099974A (en) | 2008-03-19 | 2008-03-19 | Composition comprising an extract of folium mori for preventing and treating hyperlipidemia or obesity |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20090099974A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160033063A (en) * | 2015-10-08 | 2016-03-25 | 고려대학교 산학협력단 | Pharmaceutical composition for prevention or treatment of blood vessel disease containing extracts of Morus alba stem having activity preventing from the atherogenic legion formation and foam cell formation |
| KR101876805B1 (en) * | 2016-10-18 | 2018-07-10 | 고려대학교 산학협력단 | The composition containing the ethanol extracts of Ramulus mori for preventing or treating obesity |
| KR20200053344A (en) | 2018-11-08 | 2020-05-18 | 충남대학교산학협력단 | A pharmaceutical composition comprising extract of Morus alba leaves treated with Pectinex for preventing or treating obesity |
| KR20210019051A (en) | 2021-02-10 | 2021-02-19 | 충남대학교산학협력단 | A pharmaceutical composition comprising extract of Morus alba leaves treated with Pectinex for preventing or treating obesity |
-
2008
- 2008-03-19 KR KR1020080025297A patent/KR20090099974A/en not_active Application Discontinuation
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160033063A (en) * | 2015-10-08 | 2016-03-25 | 고려대학교 산학협력단 | Pharmaceutical composition for prevention or treatment of blood vessel disease containing extracts of Morus alba stem having activity preventing from the atherogenic legion formation and foam cell formation |
| KR101876805B1 (en) * | 2016-10-18 | 2018-07-10 | 고려대학교 산학협력단 | The composition containing the ethanol extracts of Ramulus mori for preventing or treating obesity |
| KR20200053344A (en) | 2018-11-08 | 2020-05-18 | 충남대학교산학협력단 | A pharmaceutical composition comprising extract of Morus alba leaves treated with Pectinex for preventing or treating obesity |
| KR20210019051A (en) | 2021-02-10 | 2021-02-19 | 충남대학교산학협력단 | A pharmaceutical composition comprising extract of Morus alba leaves treated with Pectinex for preventing or treating obesity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20020022342A (en) | An antistress composition for a stress prevention and treatment | |
| KR100815200B1 (en) | Red ginseng mixture composition having anti-obesity activity | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| KR20090099974A (en) | Composition comprising an extract of folium mori for preventing and treating hyperlipidemia or obesity | |
| KR100516180B1 (en) | Composition for anti-hyperlipidemia | |
| EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
| WO2020091265A1 (en) | Composition comprising elderberry extract as effective component for preventing, treating, or alleviating male climacteric syndrome | |
| CN101474346B (en) | Longstamen onion bulb extract as well as preparation method and application thereof | |
| KR101910898B1 (en) | Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof | |
| KR101385657B1 (en) | Pharmaceutical Composition Comprising Herbal Extracts for Preventing or Treating Importence, and Functional Food Comprising This Extracts | |
| CN113318139A (en) | A Chinese medicinal composition used as both medicine and food for lowering blood sugar and reducing blood lipid | |
| CN110090253B (en) | Natural plant lipid-lowering composition and preparation method thereof | |
| KR102203657B1 (en) | A composition comprising the complex extract for antiobesity of women | |
| KR20140146378A (en) | A composition comprising extracts of herbal mixture for fatigue recovery as in gradient compounds | |
| KR20120115471A (en) | A composition comprising boiled powder or extract of glycine soja seed for the prevention and treatment of diabetes mellitus and diabetic complication | |
| KR100685472B1 (en) | Composition using vinegar processed ginseng preparation for treatment and prevention of type ? diabetes and metabolic syndrome | |
| KR100496622B1 (en) | Alcohol fermented food or pharmaceutical composition for prevention of obesity and process for preparation thereof | |
| CN112006136A (en) | Double-ginseng and dendrobium tea for improving abnormal blood sugar and preparation method thereof | |
| KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
| KR102501310B1 (en) | Anti-obesity composition | |
| KR102236685B1 (en) | Composition for preventing or treating lipid metabolism diseases comprising extract of salvia miltiorrhiza or paeonia lactiflora | |
| CN108077171A (en) | A kind of cultural method of reed catkins chicken | |
| CN107821538A (en) | A kind of hypoglycemic biscuit and preparation method thereof | |
| CN108066437B (en) | A Chinese medicinal composition and its preparation method | |
| KR101863603B1 (en) | Composition for prevention, improvement or treatment of arthritis comprising Mollugo pentaphylla extract as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E90F | Notification of reason for final refusal | ||
| E601 | Decision to refuse application |